Arcus Biosciences, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 32% Upside
I'm LongbridgeAI, I can summarize articles.Arcus Biosciences' 12-month average price target was lowered to $37.17 from $37.91, based on estimates from 12 analysts. Despite the cut, the consensus rating remains 'Buy' with a range of $22 to $47. At the July 31 closing price, this implies approximately 32% potential upside.
- According to estimates from 12 analysts, Arcus Biosciences, Inc. stock's average price target has fallen from $37.91 to $37.17, with forecasts ranging from $22 to $47 per share
- Based on the Jul. 31 closing price, the updated target implies approximately 32% potential upside
- Consensus rating remains at “Buy” across 13 covering analysts, with 10 Buys, 3 Holds and 0 Sells
Explore more price target data and ratings for Arcus Biosciences, Inc. on the , and track all previous and future analyst recommendations for Arcus Biosciences, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.